Xenon to Report Q3 2024 Financial Results on November 12, 2024 [Canadian Business Journal (Canada)]
Xenon to Report Q3 2024 Financial Results on November 12, 2024
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.